A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/4709 (2006.01) A61K 9/00 (2006.01) A61K 9/14 (2006.01) A61K 9/20 (2006.01) A61K 9/51 (2006.01) A61K 9/54 (2006.01) A61P 9/10 (2006.01)
Patent
CA 2611506
The present invention provides a composition comprising a platelet aggregation inhibitor, for example, cilostazol, or a salt or derivative thereof, useful in the treatment and prevention of ischemic symptoms. The invention provides a composition which comprises nanoparticulate particles comprising the platelet aggregation inhibitor and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a platelet aggregation inhibitor, or nanoparticles comprising the same, in a pulsatile or continuous manner.
La présente invention concerne une composition comprenant un inhibiteur de l'agrégation des plaquettes, par exemple, le cilostazol, ou un sel ou dérivé de celui-ci, utile dans le traitement et la prévention des symptômes ischémiques. L'invention concerne une composition qui comprend des particules nanoparticulaires comprenant l'inhibiteur de l'agrégation des plaquettes et au moins un stabilisant de surface. Les particules nanoparticulaires ont une dimension de particule moyenne efficace de moins de 2000 nm environ. L'invention concerne également une composition qui administre un inhibiteur de l'agrégation des plaquettes, ou des nanoparticules comprenant celui-ci, par impulsions ou en continu.
Devane John G.
Fanning Niall
Jenkins Scott
Liversidge Gary
Rekhi Gurvinder Singh
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Elan Pharma International Limited
LandOfFree
Nanoparticulate and controlled release compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nanoparticulate and controlled release compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nanoparticulate and controlled release compositions... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1731575